Company intelligence / Profile preview

Sinaptica Therapeutics

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Sinaptica’s rTMS-EEG closed-loop neuromodulation therapy showed >80% disease slowing across cognitive, functional, and behavioral endpoints in mild to moderate Alzheimer’s disease in placebo-controlled Phase 2 trials, with no serious side effects and high tolerability; pivotal Phase 3 clinical trials are planned for 2025

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapyNeuromodulation
Industry: Therapeutic Medical Devices

Partnerships

StartUp Health Alzheimer’s Moonshot (supported by Gates Ventures and Alzheimer’s Drug Discovery Foundation)

Beyond the preview

Go deeper on Sinaptica Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinaptica Therapeutics.

Explore the full profile